Hospital Injectable Products · LP-179
Cefazolin Powder for injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-179Hospital Injectable Products
- Generic identity
- CefazolinPowder for injection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-179
- Generic ingredient
- Cefazolin
- Dosage form
- Powder for injection
- Proposed strength
- 1 g vial; 2 g vial
- Proposed pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
About Cefazolin
Cefazolin is a cephalosporin antibiotic used in selected bacterial infections and some surgical-prophylaxis settings. It acts on bacterial cell-wall synthesis. Its spectrum and appropriate uses differ from those of other cephalosporins, so classification alone is not enough for selection. A powder-for-injection entry does not establish that the antibiotic is suitable for every operation or infection.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Infection management considers site, severity, likely organisms and microbiology, while surgical prophylaxis depends on the procedure and institutional guidance. Both require antimicrobial stewardship and review of allergy history. A vial strength should not be turned into a treatment or perioperative schedule on a corporate website. The reference monograph provides general clinical context and does not establish a specific Luang Pharma authorization or product-equivalence claim.
Important safety considerations
Severe allergy, skin reactions and antibiotic-associated diarrhoea are important risks. Kidney impairment may increase the risk of excessive exposure and neurological adverse effects. Previous severe reactions to beta-lactam antibiotics need careful assessment. Persistent or bloody diarrhoea, rash with systemic symptoms or breathing difficulty warrants urgent review. Concurrent medicines and relevant laboratory monitoring should be considered in the treatment plan.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
This source describes powder for injection in vials. Verify the salt, concentration after reconstitution, compatible diluent, authorized routes and time limits after preparation. Different vial sizes or products must not be assumed to share the same preparation instructions.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm infection or procedure-specific rationale, allergy history, kidney function and local susceptibility guidance. Match the selected vial to verified product information and the institutional protocol.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Cefazolin
- Dosage form / presentation
- Powder for injection
- Catalogue strength
- 1 g vial; 2 g vial
- Catalogue pack
- Vial; carton 10 vials
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue establishes cefazolin powder for injection in 1 g and 2 g vials but does not identify the exact salt, authorised route, reconstitution diluent, final concentration or post-reconstitution stability.
- Premixed cefazolin presentations described externally do not define these powder vials.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Cefazolin Injectiongovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical form, concentration or vial content, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-179, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-179.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.